Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C609596-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $560.90 | |
C609596-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,800.90 |
Grade | Moligand™ |
---|---|
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of EP 4 receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 4-{1-[(5R)-6-{[4-(trifluoromethyl)phenyl]methyl}-6-azaspiro[2.5]octane-5-amido]cyclopropyl}benzoic acid |
---|---|
INCHI | InChI=1S/C26H27F3N2O3/c27-26(28,29)20-5-1-17(2-6-20)16-31-14-13-24(9-10-24)15-21(31)22(32)30-25(11-12-25)19-7-3-18(4-8-19)23(33)34/h1-8,21H,9-16H2,(H,30,32)(H,33,34)/t21-/m1/s1 |
InChi Key | CADWTPLFEZSAHM-OAQYLSRUSA-N |
Canonical SMILES | O=C([C@H]1CC2(CCN1Cc1ccc(cc1)C(F)(F)F)CC2)NC1(CC1)c1ccc(cc1)C(=O)O |
PubChem CID | 133081958 |
Enter Lot Number to search for COA:
1. Caselli G, Bonazzi A, Lanza M, Ferrari F, Maggioni D, Ferioli C, Giambelli R, Comi E, Zerbi S, Perrella M et al.. (2018) Pharmacological characterisation of CR6086, a potent prostaglandin E2receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug.. Arthritis Res Ther, 20 (1): (39). [PMID:29490676] |